These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 15288287)
21. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women. Chan SS; Tam WH; Yeo W; Yu MM; Ng DP; Wong AW; Kwan WH; Yuen PM BJOG; 2007 Dec; 114(12):1510-5. PubMed ID: 17995495 [TBL] [Abstract][Full Text] [Related]
22. Adjuvant therapy for premenopausal patients with early breast cancer. Kurebayashi J Curr Opin Obstet Gynecol; 2008 Feb; 20(1):51-4. PubMed ID: 18197006 [TBL] [Abstract][Full Text] [Related]
23. Gonadotropin-releasing hormone agonists for the management of ovarian cysts in menopause breast cancer patients on tamoxifen treatment. Kourounis G; Zervoudis S; Michail G; Fotopoulos A Breast J; 2005; 11(5):365-6. PubMed ID: 16174165 [No Abstract] [Full Text] [Related]
24. Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up. Rydén L; Jönsson PE; Chebil G; Dufmats M; Fernö M; Jirström K; Källström AC; Landberg G; Stål O; Thorstenson S; Nordenskjöld B; ; Eur J Cancer; 2005 Jan; 41(2):256-64. PubMed ID: 15661551 [TBL] [Abstract][Full Text] [Related]
25. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118 [TBL] [Abstract][Full Text] [Related]
26. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Kaku H; Saika T; Tsushima T; Ebara S; Senoh T; Yamato T; Nasu Y; Kumon H Prostate; 2006 Mar; 66(4):439-44. PubMed ID: 16329145 [TBL] [Abstract][Full Text] [Related]
27. Co-occurrence of atypical endometriosis, subserous uterine leiomyomata, sactosalpinx, serous cystadenoma and bilateral hemorrhagic corpora lutea in a perimenopausal adipose patient taking tamoxifen (20 mg/day) for invasive lobular breast cancer. Ebert AD; Rosenow G; David M; Mechsner S; Magalov IS; Papadopoulos T Gynecol Obstet Invest; 2008; 66(3):209-13. PubMed ID: 18645252 [TBL] [Abstract][Full Text] [Related]
28. Ovarian cyst formation in patients using tamoxifen for breast cancer. Metindir J; Aslan S; Bilir G Jpn J Clin Oncol; 2005 Oct; 35(10):607-11. PubMed ID: 16254040 [TBL] [Abstract][Full Text] [Related]
29. Use of goserelin in the treatment of breast cancer. Rody A; Loibl S; von Minckwitz G; Kaufmann M Expert Rev Anticancer Ther; 2005 Aug; 5(4):591-604. PubMed ID: 16111461 [TBL] [Abstract][Full Text] [Related]
30. [MR Imaging of the pelvis in the diagnosis of the endometrium in breast cancer patients in tamoxifen therapy]. Hauth E; Libera H; Kimmig R; Forsting M Rofo; 2006 Mar; 178(3):316-23. PubMed ID: 16508840 [TBL] [Abstract][Full Text] [Related]
31. Effect of adjuvant systemic treatment on cosmetic outcome and late normal-tissue reactions after breast conservation. Johansen J; Overgaard J; Overgaard M Acta Oncol; 2007; 46(4):525-33. PubMed ID: 17497320 [TBL] [Abstract][Full Text] [Related]
32. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. ; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417 [TBL] [Abstract][Full Text] [Related]
33. [Adjuvant chemotherapy of premenopausal breast cancer with LH-RH analogue for ovarian protection--a case report]. Asaga S; Ando J; Arai T; Fujii H Gan To Kagaku Ryoho; 2005 Jul; 32(7):1069-72. PubMed ID: 16044976 [TBL] [Abstract][Full Text] [Related]
34. Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial. Alkner S; Bendahl PO; Fernö M; Nordenskjöld B; Rydén L; Eur J Cancer; 2009 Sep; 45(14):2496-502. PubMed ID: 19535242 [TBL] [Abstract][Full Text] [Related]
35. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. Rydén L; Jirström K; Bendahl PO; Fernö M; Nordenskjöld B; Stål O; Thorstenson S; Jönsson PE; Landberg G J Clin Oncol; 2005 Jul; 23(21):4695-704. PubMed ID: 16034044 [TBL] [Abstract][Full Text] [Related]
36. Tamoxifen use and endometrial lesions: hysteroscopic, histological, and immunohistochemical findings in postmenopausal women with breast cancer. Dibi RP; Zettler CG; Pessini SA; Ayub AV; de Almeida SB; da Silveira GP Menopause; 2009; 16(2):293-300. PubMed ID: 19034048 [TBL] [Abstract][Full Text] [Related]
38. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women. Mouridsen HT Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085 [TBL] [Abstract][Full Text] [Related]
39. [Effectiveness of LH-RH agonist for bone metastases of breast cancer--report of a case]. Kudoh S; Kawamura H; Suzuki Y; Matsuzaki M; Nishina M; Tsukamoto M Gan To Kagaku Ryoho; 1996 May; 23(6):787-90. PubMed ID: 8645031 [TBL] [Abstract][Full Text] [Related]